Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

10
What Is Going On At Axovant Sciences?

2018-08-15 seekingalpha
On February 12, 2018, Axovant Sciences (AXON) issued a press release noting changes to the management team and Board of Directors. Dr David Hung retired as CEO and Dr Pavan Cheruvu took his place, among other changes. Three and a half months of radio silence followed. What broke the silence? Another press release on May 29 noting additions to the management team and organizational restructuring. Things got interesting on June 6, when AXON reported it had licensed a gene therapy for Parkinson’s disease from Oxford BioMedica and of course made additional management changes.
ACAD OXB OXBDF AXON

0
Market report: Shares struggle as sterling falls to lowest level since September

2018-08-06 telegraph.co.uk
Mounting fears in the City of a no-deal Brexit dragged the pound down to an 11-month low as the FTSE 100 stagnated amid heightened trade war worries.
OXB OXBDF JLIF

5
Oxford BioMedica, UK Cystic Fibrosis Gene Therapy Consortium, Boehringer Ingelheim and Imperial Innovations Form Partnership to Develop a Novel Gene Therapy Treatment for Cystic Fibrosis

2018-08-06 globenewswire
Oxford BioMedica, UK Cystic Fibrosis Gene Therapy Consortium, Boehringer Ingelheim and Imperial Innovations Form Partnership to Develop a Novel Gene Therapy Treatment for Cystic Fibrosis
IMDZ OXB OXBDF

7
Axovant Sciences Failed To Mention Critical Information

2018-07-15 seekingalpha
On July 10th 2018 Axovant Sciences (AXON) announced a partnership with Benitec Biopharma (BNTC) for exclusive global rights to BB-301, now named AXO-AAV-OPMD, for the treatment of oculopharyngeal muscular dystrophy, or OPMD, and five additional gene therapy programs in neurological disorders.
BLT OXB BNTC BNIKF OXBDF AXON BNTCW

7
Axovant, Benitec Gain on Licensing Deal for Gene Therapy

2018-07-10 zacks
Shares of Axovant Sciences (AXON - Free Report) gained after it announced a licensing agreement with Benitec Biopharma .
UNP BLT SLDB OXB BNTC BNIKF OXBDF AXON BNTCW

5
Axovant Licenses Benitec Gene Therapy Candidates for OPMD, Neurological Disorders

2018-07-09 genengnews
Benitec Biopharma could generate up to $655 million-plus in payments from licensing its preclinical gene therapy for oculopharyngeal muscular dystrophy (OPMD; pictured), and five additional Benitec gene therapy candidates for neurological disorders to to Axovant Sciences. [NIH]
BLT OXB BNTC BNIKF OXBDF ONCE BNTCW AXON

5
Axonant Showing Signs Of A Comeback As FDA Increases Scrutiny Of Compounding

2018-07-06 seekingalpha
The overall bioscience market traded with a mixed sentiment for the day. Many equities under our coverage continued to log in further profits for investors.
OXB ESPR IBB XBI OXBDF ONCE AXON

216
Voyager's Parkinson's Gene Therapy Is Likely To Fail

2018-07-01 seekingalpha
Voyager needs to raises money; it will most likely be an equity offering before phase 1b and phase 1 posterior trajectory data is released.
VYGR OXB OXBDF SNY AXON

217
Rounds Report: Axovant Rallied While The FDA Approved Epidiolex

2018-06-27 seekingalpha
We look for a horse with one chance in two of winning and which pays you three to one. - Charlie Munger
DOVA GWPH OXB IBB XBI OXBDF ONCE GWP AXON

213
A Deep Dive Into Axovant's Parkinson's Gene Therapy

2018-06-25 seekingalpha
Axovant will be initiating a clinical trial with a second-generation gene therapy AXO-Lenti-PD later this year.
OXB OXBDF AXON

213
Solid (SLDB) Surges as FDA Lifts Clinical Hold on DMD Drug

2018-06-19 zacks
Shares of Solid Biosciences Inc. (SLDB - Free Report) surged 10.9% after the company announced that the FDA has lifted the clinical hold on its phase I/II trial, IGNITE DMD, for its experimental candidate, SGT-001.
SLDB OXB OXBDF NEE AXON

215
Axovant's Parkinson's Gene Therapy Is Extremely Risky

2018-06-19 seekingalpha
Axovant purchased an experimental Parkinson's gene therapy and is expected to start a clinical trial later this year.
ARNA OXB OXBDF AXON

217
Gene Therapy Prospects Make Axovant Sciences A Compelling Buy For 2018

2018-06-15 seekingalpha
Axovant Sciences' (AXON) licensing deal with Oxford BioMedica (OTCPK:OXBDF) is nothing short of a masterstroke. This deal has opened up the gene therapy segment for Axovant Sciences and has positioned the company to make a solid entry in the neurodegenerative disease segment. This transformation from being a small molecule player to a very potent lentiviral vector gene therapy company initially targeting Parkinson's disease or PD has been well received by the investor community.
OXB NVS OXBDF SNY AXON

370
Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod

2018-06-13 zacks
The biotech sector was in focus last week with regular pipeline updates and collaboration/licensing deals. While biotech bigwig Amgen’s (AMGN - Free Report) drugs won both FDA and EC approvals, Axovant (AXON - Free Report) soared on a licensing deal Oxford BioMedica. Meanwhile, Regeneron (REGN - Free Report) collaborated with Zoetis to discover new veterinary treatments.
AMGN ALXN BIIB OXB OXBDF AXON

216
Axovant Sciences: Expect A Crash After An Overhyped Deal With Oxford BioMedica

2018-06-12 seekingalpha
Axovant Sciences skyrocketed after a licensing agreement with Oxford BioMedica and investment by Roivant, resulting in a $373 million increase to its valuation.
IMDZ OXB LNSTY OXBDF AXON

Related Articles

RNVA: Rennova Health Analysis and Research Report

1h - Asif

Business overview Rennova Health, Inc. (together with its subsidiaries, “Rennova”, “we” or the “Company”) is a provider of an expanding group of health care services for healthcare providers, patients and individuals. Beginning in 2018, the Company intends to focus on and operate two synergistic divisions: 1) Clinical diagnostics through its clinical laboratories; and 2) Hospital operations through its Big South Fork Medical Center, which opened on August 8, 2017, and a hospital in Jamestown Tennessee, including a doctor’s practice, the assets of which the company expect to acquire in the second quarter of 2018, pursuant to the terms of a definitive asset purchase agreement that the company entered into on January 31, 2018, as more fully discussed below. The company believe that its approach will produce a more sustainable business model and the capture of multiple revenue streams from medical providers, patients and hospital services. Management determined that because Big So...

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...